FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029152314> ?p ?o ?g. }

• W2029152314 endingPage "1561" @default.
• W2029152314 startingPage "1553" @default.
• W2029152314 abstract "To compare the virologic activity of continued lamivudine (3TC) versus a switch to delavirdine (DLV) when initiating protease inhibitor therapy in nucleoside-experienced patients.Randomized, open-label, multi-center study.Adult AIDS clinical trials units.Protease and non-nucleoside reverse transcriptase inhibitor-naive patients who had received 3TC plus zidovudine (ZDV), stavudine (d4T), or didanosine (ddl) for at least 24 weeks.Patients with plasma HIV-1 RNA levels > 500 copies/ml who previously received d4T + 3TC or ddI + 3TC were randomized to ZDV + 3TC + indinavir (IDV) or ZDV + DLV + IDV.Primary endpoints were the proportion of patients with plasma HIV-1 RNA levels < or = 200 copies/ml at 24 weeks, and occurrence of serious adverse events. The proportion of patients with plasma HIV-1 RNA levels < or = 200 copies/ml at week 48 was a secondary endpoint.At week 24, 58% of subjects in the ZDV + 3TC + IDV arm and 73% in the ZDV + DLV + IDV arm had plasma HIV-1 RNA levels < or = 200 copies/ml (P = 0.29). At week 48, plasma HIV-1 RNA levels were < or = 200 copies/ml in 48% and 83%, respectively (P = 0.007). Rash and hyperbilirubinemia occurred more frequently in the DLV arm than in the 3TC arm. Steady-state plasma IDV levels were higher among patients in the DLV arm as compared with the 3TC arm.Substituting DLV for 3TC when adding IDV improved virologic outcome in nucleoside-experienced patients. This result might be explained, in part, by the positive effect of DLV on IDV pharmacokinetics." @default.
• W2029152314 created "2016-06-24" @default.
• W2029152314 creator A5003569285 @default.
• W2029152314 creator A5005048904 @default.
• W2029152314 creator A5017415232 @default.
• W2029152314 creator A5021176687 @default.
• W2029152314 creator A5024560316 @default.
• W2029152314 creator A5027845051 @default.
• W2029152314 creator A5028669057 @default.
• W2029152314 creator A5032551749 @default.
• W2029152314 creator A5034738230 @default.
• W2029152314 creator A5041036157 @default.
• W2029152314 creator A5055354231 @default.
• W2029152314 creator A5058715015 @default.
• W2029152314 creator A5086281463 @default.
• W2029152314 date "2000-07-01" @default.
• W2029152314 modified "2023-09-27" @default.
• W2029152314 title "Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370" @default.
• W2029152314 cites W1972807883 @default.
• W2029152314 cites W1982448824 @default.
• W2029152314 cites W1991230378 @default.
• W2029152314 cites W1998085351 @default.
• W2029152314 cites W1999347854 @default.
• W2029152314 cites W2000488513 @default.
• W2029152314 cites W2021037491 @default.
• W2029152314 cites W2026219081 @default.
• W2029152314 cites W2026323517 @default.
• W2029152314 cites W2035938088 @default.
• W2029152314 cites W2055008556 @default.
• W2029152314 cites W2057392755 @default.
• W2029152314 cites W2080198736 @default.
• W2029152314 cites W2099697190 @default.
• W2029152314 cites W2101754090 @default.
• W2029152314 cites W2121802915 @default.
• W2029152314 cites W2123101436 @default.
• W2029152314 cites W2131582834 @default.
• W2029152314 cites W2133315239 @default.
• W2029152314 cites W2137262613 @default.
• W2029152314 cites W2144838726 @default.
• W2029152314 cites W2149335010 @default.
• W2029152314 cites W2317442966 @default.
• W2029152314 cites W2916044971 @default.
• W2029152314 doi "https://doi.org/10.1097/00002030-200007280-00011" @default.
• W2029152314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10983642" @default.
• W2029152314 hasPublicationYear "2000" @default.
• W2029152314 type Work @default.
• W2029152314 sameAs 2029152314 @default.
• W2029152314 citedByCount "19" @default.
• W2029152314 countsByYear W20291523142012 @default.
• W2029152314 crossrefType "journal-article" @default.
• W2029152314 hasAuthorship W2029152314A5003569285 @default.
• W2029152314 hasAuthorship W2029152314A5005048904 @default.
• W2029152314 hasAuthorship W2029152314A5017415232 @default.
• W2029152314 hasAuthorship W2029152314A5021176687 @default.
• W2029152314 hasAuthorship W2029152314A5024560316 @default.
• W2029152314 hasAuthorship W2029152314A5027845051 @default.
• W2029152314 hasAuthorship W2029152314A5028669057 @default.
• W2029152314 hasAuthorship W2029152314A5032551749 @default.
• W2029152314 hasAuthorship W2029152314A5034738230 @default.
• W2029152314 hasAuthorship W2029152314A5041036157 @default.
• W2029152314 hasAuthorship W2029152314A5055354231 @default.
• W2029152314 hasAuthorship W2029152314A5058715015 @default.
• W2029152314 hasAuthorship W2029152314A5086281463 @default.
• W2029152314 hasBestOaLocation W20291523141 @default.
• W2029152314 hasConcept C126322002 @default.
• W2029152314 hasConcept C142462285 @default.
• W2029152314 hasConcept C159047783 @default.
• W2029152314 hasConcept C2522874641 @default.
• W2029152314 hasConcept C2777210460 @default.
• W2029152314 hasConcept C2777351918 @default.
• W2029152314 hasConcept C2777447569 @default.
• W2029152314 hasConcept C2777869810 @default.
• W2029152314 hasConcept C2779889181 @default.
• W2029152314 hasConcept C2780216070 @default.
• W2029152314 hasConcept C2780593183 @default.
• W2029152314 hasConcept C2780727368 @default.
• W2029152314 hasConcept C2993143319 @default.
• W2029152314 hasConcept C71924100 @default.
• W2029152314 hasConcept C90924648 @default.
• W2029152314 hasConcept C98274493 @default.
• W2029152314 hasConceptScore W2029152314C126322002 @default.
• W2029152314 hasConceptScore W2029152314C142462285 @default.
• W2029152314 hasConceptScore W2029152314C159047783 @default.
• W2029152314 hasConceptScore W2029152314C2522874641 @default.
• W2029152314 hasConceptScore W2029152314C2777210460 @default.
• W2029152314 hasConceptScore W2029152314C2777351918 @default.
• W2029152314 hasConceptScore W2029152314C2777447569 @default.
• W2029152314 hasConceptScore W2029152314C2777869810 @default.
• W2029152314 hasConceptScore W2029152314C2779889181 @default.
• W2029152314 hasConceptScore W2029152314C2780216070 @default.
• W2029152314 hasConceptScore W2029152314C2780593183 @default.
• W2029152314 hasConceptScore W2029152314C2780727368 @default.
• W2029152314 hasConceptScore W2029152314C2993143319 @default.
• W2029152314 hasConceptScore W2029152314C71924100 @default.
• W2029152314 hasConceptScore W2029152314C90924648 @default.
• W2029152314 hasConceptScore W2029152314C98274493 @default.
• W2029152314 hasIssue "11" @default.
• W2029152314 hasLocation W20291523141 @default.

• next